12.40
前日終値:
$11.89
開ける:
$12.1
24時間の取引高:
638.27K
Relative Volume:
0.83
時価総額:
$909.40M
収益:
$125.58M
当期純損益:
$-92.14M
株価収益率:
-9.9807
EPS:
-1.2424
ネットキャッシュフロー:
$-138.27M
1週間 パフォーマンス:
+6.99%
1か月 パフォーマンス:
+3.51%
6か月 パフォーマンス:
+20.04%
1年 パフォーマンス:
+4.91%
Xencor Inc Stock (XNCR) Company Profile
Compare XNCR vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
XNCR
Xencor Inc
|
12.40 | 872.00M | 125.58M | -92.14M | -138.27M | -1.2424 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-10-29 | アップグレード | Barclays | Underweight → Overweight |
| 2025-09-17 | 再開されました | Barclays | Underweight |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2024-12-12 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 繰り返されました | BTIG Research | Buy |
| 2024-02-28 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 開始されました | BofA Securities | Buy |
| 2022-12-06 | 開始されました | Cowen | Outperform |
| 2022-10-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-21 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-02-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2020-02-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-01-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-08-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-04-12 | 開始されました | Guggenheim | Buy |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2017-03-02 | 開始されました | Instinet | Neutral |
| 2017-03-02 | 繰り返されました | Wedbush | Outperform |
| 2016-10-04 | 開始されました | Piper Jaffray | Overweight |
| 2015-12-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-05 | 繰り返されました | MLV & Co | Buy |
| 2015-02-12 | 繰り返されました | Oppenheimer | Outperform |
| 2015-01-28 | 繰り返されました | MLV & Co | Buy |
| 2014-07-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Xencor Inc (XNCR) 最新ニュース
Xencor (NASDAQ:XNCR) Shares Gap DownTime to Sell? - MarketBeat
JPMorgan Chase & Co. Reiterates Neutral Rating for Xencor (NASDAQ:XNCR) - MarketBeat
JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18 - marketscreener.com
Xencor stock downgraded to neutral at JPMorgan on execution concerns - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Patterns Watch: Is Xencor Inc stock a good pick for beginners2026 Buyback Activity & Safe Entry Trade Signal Reports - baoquankhu1.vn
How Xencor Inc. (XNCR) Affects Rotational Strategy Timing - Stock Traders Daily
XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Upgrade: What is the Moat Score of Xencor Inc2026 Selloffs & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Retail Trends: Can Xencor Inc beat the S P 500Quarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Earnings Recap: Is Xencor Inc backed by strong institutional buying2026 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Braidwell LP Lowers Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - TipRanks
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans By Investing.com - Investing.com South Africa
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor, Genentech to End Protein Therapeutics Collaboration - TipRanks
Xencor (XNCR) SVP and general counsel sells 5,011 shares for RSU tax - Stock Titan
Xencor (XNCR) CFO sells 2,517 shares to cover RSU tax withholding - Stock Titan
Xencor (XNCR) CEO sells 21,476 shares to cover RSU tax obligations - Stock Titan
Genentech ends Xencor (NASDAQ: XNCR) efbalropendekin alfa license deal - Stock Titan
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Insider Bassil I. Dahiyat sells and vests shares (XNCR) — 12/19/2025 to 03/05/2026 - Stock Titan
Retail Trends: Is Xencor Inc impacted by rising rates2025 Historical Comparison & Consistent Profit Trading Strategies - baoquankhu1.vn
Resistance Check: What is the long term forecast for Xencor Inc stock2025 Key Highlights & Community Consensus Picks - baoquankhu1.vn
Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc. - MarketBeat
RBC Capital Reaffirms Their Buy Rating on Xencor (XNCR) - The Globe and Mail
Dahiyat, Xencor CEO, sells $80k in XNCR stock By Investing.com - Investing.com Australia
3,244-share sale planned by XNCR (NASDAQ: XNCR) — insider notice - Stock Titan
Insider sale and restricted vesting reported by Company (NASDAQ: XNCR) - Stock Titan
[144] Xencor Inc SEC Filing - Stock Titan
Xencor SVP Eckert sells $17,747 in shares By Investing.com - Investing.com Australia
Xencor faces royalty dispute with Alexion over Ultomiris sales By Investing.com - Investing.com Australia
Xencor Inc (XNCR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):